Hercules Capital Provides $30MM Debt Facility to HiberCell
HiberCell, a biotechnology company developing therapeutics for the prevention of cancer relapse and metastasis, closed on a $30 million debt facility with Hercules Capital. In addition, HiberCell completed a Series B financing round for gross proceeds of $67.4 million.
May 20, 2021
Alan Rigby | ARCH Venture Partners | Bristol-Myers Squibb | Hercules Capital | HiberCell | Huizenga Capital Management | Magnetic Ventures | Monashee Investment Management | Mount Sinai Innovation Partners | Rene Mora | Tekla Capital Management | Trinitas Capital
Ian Koplin